{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:32:09Z","timestamp":1777926729097,"version":"3.51.4"},"reference-count":49,"publisher":"American Association for Cancer Research (AACR)","issue":"24","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oncolytic virus therapy is being evaluated in clinical trials for human glioma. While it is widely assumed that the immune response of the patient to the virus infection limits the utility of the therapy, investigations into the specific cell type(s) involved in this response have been performed using nonspecific pharmacologic inhibitors or allogeneic models with compromised immunity. To identify the immune cells that participate in clearing an oncolytic infection in glioma, we used flow cytometry and immunohistochemistry to immunophenotype an orthotopic glioma model in immunocompetent mice after Myxoma virus (MYXV) administration. These studies revealed a large resident microglia and macrophage population in untreated tumors, and robust monocyte, T-, and NK cell infiltration 3 days after MYXV infection. To determine the role on the clinical utility of MYXV therapy for glioma, we used a combination of knockout mouse strains and specific immunocyte ablation techniques. Collectively, our experiments identify an important role for tumor-resident myeloid cells and overlapping roles for recruited NK and T cells in the clearance and efficacy of oncolytic MYXV from gliomas. Using a cyclophosphamide regimen to achieve lymphoablation prior and during MYXV treatment, we prevented treatment-induced peripheral immunocyte recruitment and, surprisingly, largely ablated the tumor-resident macrophage population. Virotherapy of cyclophosphamide-treated animals resulted in sustained viral infection within the glioma as well as a substantial survival advantage. This study demonstrates that resistance to MYXV virotherapy in syngeneic glioma models involves a multifaceted cellular immune response that can be overcome with cyclophosphamide-mediated lymphoablation. Cancer Res; 74(24); 7260\u201373. \u00a92014 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-14-0876","type":"journal-article","created":{"date-parts":[[2014,10,21]],"date-time":"2014-10-21T23:40:13Z","timestamp":1413934813000},"page":"7260-7273","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Cellular Factors Promoting Resistance to Effective Treatment of Glioma with Oncolytic Myxoma Virus"],"prefix":"10.1158","volume":"74","author":[{"given":"Franz J.","family":"Zemp","sequence":"first","affiliation":[{"name":"1Southern Alberta Cancer Research Institute, University of Calgary, Alberta, Canada."},{"name":"2Clark H. Smith Brain Tumor Center, University of Calgary, Alberta, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brienne A.","family":"McKenzie","sequence":"additional","affiliation":[{"name":"1Southern Alberta Cancer Research Institute, University of Calgary, Alberta, Canada."},{"name":"2Clark H. Smith Brain Tumor Center, University of Calgary, Alberta, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqing","family":"Lun","sequence":"additional","affiliation":[{"name":"1Southern Alberta Cancer Research Institute, University of Calgary, Alberta, Canada."},{"name":"2Clark H. Smith Brain Tumor Center, University of Calgary, Alberta, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karlyne M.","family":"Reilly","sequence":"additional","affiliation":[{"name":"3Mouse Cancer Genetics Program, NCI, Frederick, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant","family":"McFadden","sequence":"additional","affiliation":[{"name":"4Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, Florida."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. Wee","family":"Yong","sequence":"additional","affiliation":[{"name":"5Hotchkiss Brain Institute, Departments of Clinical Neurosciences, University of Calgary, Alberta, Canada."},{"name":"6Hotchkiss Brain Institute, Department of Oncology, University of Calgary, Alberta, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Forsyth","sequence":"additional","affiliation":[{"name":"1Southern Alberta Cancer Research Institute, University of Calgary, Alberta, Canada."},{"name":"2Clark H. Smith Brain Tumor Center, University of Calgary, Alberta, Canada."},{"name":"7Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute and University of Southern Florida, Tampa, Florida."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2014,12,14]]},"reference":[{"key":"2022061704590909300_bib1","author":"Canadian Cancer Society"},{"key":"2022061704590909300_bib2","author":"Cancer Facts and Figures 2014. American Cancer Society"},{"key":"2022061704590909300_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2022061704590909300_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cytogfr.2010.04.001","article-title":"Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil","volume":"21","author":"Zemp","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"2022061704590909300_bib5","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/neuonc\/not310","article-title":"Glioma virus therapies between bench and bedside","volume":"16","author":"Kaufmann","year":"2014","journal-title":"Neuro Oncol"},{"key":"2022061704590909300_bib6","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"2022061704590909300_bib7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/sj.cgt.7700750","article-title":"Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization","volume":"12","author":"Conrad","year":"2005","journal-title":"Cancer Gene Ther"},{"key":"2022061704590909300_bib8","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm0995-938","article-title":"Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas","volume":"1","author":"Mineta","year":"1995","journal-title":"Nat Med"},{"key":"2022061704590909300_bib9","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1073\/pnas.97.12.6803","article-title":"Intergeneric poliovirus recombinants for the treatment of malignant glioma","volume":"97","author":"Gromeier","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061704590909300_bib10","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jnci\/93.12.903","article-title":"Reovirus as an oncolytic agent against experimental human malignant gliomas","volume":"93","author":"Wilcox","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"2022061704590909300_bib11","doi-asserted-by":"crossref","first-page":"e65801","DOI":"10.1371\/journal.pone.0065801","article-title":"Resistance to oncolytic myxoma virus therapy in nf1(-\/-)\/trp53(-\/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon","volume":"8","author":"Zemp","year":"2013","journal-title":"PLoS ONE"},{"key":"2022061704590909300_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1215\/S1152851705000074","article-title":"Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model","volume":"7","author":"Hellums","year":"2005","journal-title":"Neuro Oncol"},{"key":"2022061704590909300_bib13","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1158\/0008-5472.CAN-08-3886","article-title":"Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors","volume":"69","author":"Wakimoto","year":"2009","journal-title":"Cancer Res"},{"key":"2022061704590909300_bib14","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1038\/mt.2010.183","article-title":"Efficacy and safety\/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma","volume":"18","author":"Lun","year":"2010","journal-title":"Mol Ther"},{"key":"2022061704590909300_bib15","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/0008-5472.CAN-09-1510","article-title":"Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin","volume":"70","author":"Lun","year":"2010","journal-title":"Cancer Res"},{"key":"2022061704590909300_bib16","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/neuonc\/not035","article-title":"Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin","volume":"15","author":"Zemp","year":"2013","journal-title":"Neuro Oncol"},{"key":"2022061704590909300_bib17","doi-asserted-by":"crossref","first-page":"e66825","DOI":"10.1371\/journal.pone.0066825","article-title":"Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo","volume":"8","author":"Ogbomo","year":"2013","journal-title":"PLoS ONE"},{"key":"2022061704590909300_bib18","doi-asserted-by":"crossref","first-page":"8818","DOI":"10.1158\/0008-5472.CAN-07-1214","article-title":"Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin","volume":"67","author":"Lun","year":"2007","journal-title":"Cancer Res"},{"key":"2022061704590909300_bib19","doi-asserted-by":"crossref","first-page":"9982","DOI":"10.1158\/0008-5472.CAN-05-1201","article-title":"Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas","volume":"65","author":"Lun","year":"2005","journal-title":"Cancer Res"},{"key":"2022061704590909300_bib20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/mt.2008.228","article-title":"Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM","volume":"17","author":"Markert","year":"2009","journal-title":"Mol Ther"},{"key":"2022061704590909300_bib21","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/sj.gt.3301664","article-title":"The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study","volume":"9","author":"Papanastassiou","year":"2002","journal-title":"Gene Ther"},{"key":"2022061704590909300_bib22","doi-asserted-by":"crossref","first-page":"12873","DOI":"10.1073\/pnas.0605496103","article-title":"Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses","volume":"103","author":"Fulci","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061704590909300_bib23","doi-asserted-by":"crossref","first-page":"9398","DOI":"10.1158\/0008-5472.CAN-07-1063","article-title":"Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses","volume":"67","author":"Fulci","year":"2007","journal-title":"Cancer Res"},{"key":"2022061704590909300_bib24","doi-asserted-by":"crossref","first-page":"11840","DOI":"10.1158\/0008-5472.CAN-06-1200","article-title":"Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity","volume":"66","author":"Allen","year":"2006","journal-title":"Cancer Res"},{"key":"2022061704590909300_bib25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1215\/15228517-2006-008","article-title":"The role of human glioma-infiltrating microglia\/macrophages in mediating antitumor immune responses","volume":"8","author":"Hussain","year":"2006","journal-title":"Neuro Oncol"},{"key":"2022061704590909300_bib26","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3171\/2008.7.JNS08475","article-title":"Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation","volume":"110","author":"Parney","year":"2009","journal-title":"J Neurosurg"},{"key":"2022061704590909300_bib27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s004010050520","article-title":"Distribution and characterization of microglia\/macrophages in human brain tumors","volume":"92","author":"Roggendorf","year":"1996","journal-title":"Acta Neuropathol"},{"key":"2022061704590909300_bib28","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1128\/JVI.05545-11","article-title":"The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5\/T-BET signaling and generation of gamma interferon","volume":"86","author":"Alvarez-Breckenridge","year":"2012","journal-title":"J Virol"},{"key":"2022061704590909300_bib29","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/nm.3013","article-title":"NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors","volume":"18","author":"Alvarez-Breckenridge","year":"2012","journal-title":"Nat Med"},{"key":"2022061704590909300_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/79075","article-title":"Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects","volume":"26","author":"Reilly","year":"2000","journal-title":"Nat Genet"},{"key":"2022061704590909300_bib31","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/mt.2011.293","article-title":"Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer","volume":"20","author":"Wennier","year":"2012","journal-title":"Mol Ther"},{"key":"2022061704590909300_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/9780471729259.mc14a01s17","article-title":"Myxoma virus: propagation, purification, quantification, and storage","author":"Smallwood","year":"2010","journal-title":"Curr Protoc Microbiol"},{"key":"2022061704590909300_bib33","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1152\/physrev.00011.2010","article-title":"Physiology of microglia","volume":"91","author":"Kettenmann","year":"2011","journal-title":"Physiol Rev"},{"key":"2022061704590909300_bib34","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1084\/jem.193.6.713","article-title":"Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis","volume":"193","author":"Huang","year":"2001","journal-title":"J Exp Med"},{"key":"2022061704590909300_bib35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.brainres.2009.06.054","article-title":"The role of CC chemokine receptor 2 on microglia activation and blood-borne cell recruitment after transient focal cerebral ischemia in mice","volume":"1289","author":"Schilling","year":"2009","journal-title":"Brain Res"},{"key":"2022061704590909300_bib36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4049\/jimmunol.1003003","article-title":"Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in West Nile virus encephalitis","volume":"186","author":"Lim","year":"2011","journal-title":"J Immunol"},{"key":"2022061704590909300_bib37","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.4049\/jimmunol.172.7.4410","article-title":"Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response","volume":"172","author":"Sunderkotter","year":"2004","journal-title":"J Immunol"},{"key":"2022061704590909300_bib38","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.172.4.1025","article-title":"Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages","volume":"172","author":"Huitinga","year":"1990","journal-title":"J Exp Med"},{"key":"2022061704590909300_bib39","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/neuonc\/not073","article-title":"Inhibition of glioma growth by minocycline is mediated through endoplasmic reticulum stress-induced apoptosis and autophagic cell death","volume":"15","author":"Liu","year":"2013","journal-title":"Neuro Oncol"},{"key":"2022061704590909300_bib40","doi-asserted-by":"crossref","first-page":"e18688","DOI":"10.1371\/journal.pone.0018688","article-title":"Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV neuroAIDS","volume":"6","author":"Campbell","year":"2011","journal-title":"PLoS ONE"},{"key":"2022061704590909300_bib41","doi-asserted-by":"crossref","first-page":"15769","DOI":"10.1073\/pnas.95.26.15769","article-title":"Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia","volume":"95","author":"Yrjanheikki","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061704590909300_bib42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/1074-7613(95)90047-0","article-title":"Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain","volume":"2","author":"Cao","year":"1995","journal-title":"Immunity"},{"key":"2022061704590909300_bib43","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1158\/1078-0432.CCR-08-2342","article-title":"Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide","volume":"15","author":"Lun","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022061704590909300_bib44","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of gammadelta T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"2022061704590909300_bib45","doi-asserted-by":"crossref","first-page":"e1002838","DOI":"10.1371\/journal.ppat.1002838","article-title":"Invariant NKT cells: regulation and function during viral infection","volume":"8","author":"Juno","year":"2012","journal-title":"PLoS Pathog"},{"key":"2022061704590909300_bib46","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/jcbfm.2012.6","article-title":"Importance of T lymphocytes in brain injury, immunodeficiency, and recovery after cerebral ischemia","volume":"32","author":"Brait","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"key":"2022061704590909300_bib47","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-immunol-032712-095951","article-title":"Regulation of ligands for the NKG2D activating receptor","volume":"31","author":"Raulet","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"2022061704590909300_bib48","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/2326-6066.CIR-14-0015","article-title":"Oncolytic viruses and their application to cancer immunotherapy","volume":"2","author":"Chiocca","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2022061704590909300_bib49","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/74\/24\/7260\/2713824\/7260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/74\/24\/7260\/2713824\/7260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T11:02:39Z","timestamp":1655463759000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/74\/24\/7260\/599255\/Cellular-Factors-Promoting-Resistance-to-Effective"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,14]]},"references-count":49,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2014,12,14]]},"published-print":{"date-parts":[[2014,12,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-14-0876","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6506156","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22402796.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22402793.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22402796","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6506156.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22402793","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,14]]}}}